The AACR annual meeting concluded on April 13, showcasing hundreds of preclinical to late-stage information from ongoing studies on treatment candidates.
GSK is acquiring Sierra Oncology for $1.9 billion in a deal expected to help both companies take a major step in developing a treatment for rare types of cancer.
The FDA’s decision to lift the hold directive on April 11 involving the investigational drug magrolimab follows a comprehensive review of each trial’s safety data.
The week began with new partnerships formed in the life sciences industry as several firms entered into licensing deals and collaboration commitments. Here’s a look at the latest.
Shares fell in several life sciences companies at the close of the market Friday on apparently lackluster early data from their respective research projects. We look into each one below:
GENFIT delivered on its promise to improve its financial situation in the year to December 31, 2021, posting an income of $40.8 million USD from a loss of $20.3 million in the year prior.
The company presented an update on its Phase III LAVENDER study of trofinetide for Rett syndrome at the American Academy of Neurology’s annual meeting in Seattle.
New data from Roche’s study on the use of Ocrevus to treat patients with primary and secondary progressive multiple sclerosis demonstrated positive outcomes.
